Search
                    Virginia Paid Clinical Trials
A listing of 1861  clinical trials  in Virginia  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1 - 12 of 1861
        
                Virginia is currently home to 1861 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
            
                                                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    
                
                                    A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
                                
            
            
        Recruiting
                            
            
                This Phase IIb dose-ranging study will evaluate the efficacy and safety of 3 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive pulmonary disease.             
        
        
    Gender:
                ALL
            Ages:
                40 years and above
            Trial Updated:
                08/22/2025
            
            Locations: Research Site, Norfolk, Virginia         
        
        
            Conditions: Chronic Obstructive Pulmonary Disease (COPD)
        
            
        
    
                
                                    The Vanguard Study: Testing a New Way to Screen for Cancer
                                
            
            
        Recruiting
                            
            
                The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for multiple cancers simultaneously. There is a need to understand how MCDs may work as cancer screening tools. The goal of cancer screening is to reduce the burden of cancer by identifying cancers before they show symptoms or signs, when treatment is likely to be most...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 45 years and 75 years
            Trial Updated:
                08/22/2025
            
            Locations: Sentara Martha Jefferson Hospital, Charlottesville, Virginia         
        
        
            Conditions: Bladder Carcinoma, Breast Carcinoma, Colorectal Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Liver Carcinoma, Lung Carcinoma, Malignant Solid Neoplasm, Ovarian Carcinoma, Pancreatic Carcinoma, Prostate Carcinoma
        
            
        
    
                
                                    Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.             
        
        
    Gender:
                ALL
            Ages:
                12 years and above
            Trial Updated:
                08/22/2025
            
            Locations: Investigative Site US248, Arlington, Virginia         
        
        
            Conditions: Hidradenitis Suppurativa
        
            
        
    
                
                                    Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
                                
            
            
        Recruiting
                            
            
                TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop the growth of cancer cells. This is done either by killing the cells or by stopping them from growing. The purpose of this study is to learn about possible side effects of TIVDAK, specially to any side effect that is related to the eye. A side effect is anything a medicine does to your body that is not part of how the medicine treats disease.
* This...  Read More             
        
        
    Gender:
                FEMALE
            Ages:
                18 years and above
            Trial Updated:
                08/22/2025
            
            Locations: University of Virginia Comprehensive Cancer Center, Charlottesville, Virginia         
        
        
            Conditions: Cervical Cancer
        
            
        
    
                
                                    Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
                                
            
            
        Recruiting
                            
            
                The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/22/2025
            
            Locations: University of Virginia Health System, Charlottesville, Virginia         
        
        
            Conditions: Carcinoma, Non-Small-Cell Lung
        
            
        
    
                
                                    Pivotal Study of Voro Urologic Scaffold
                                
            
            
        Recruiting
                            
            
                The objective of this study is to compare safety and effectiveness of the Voro Urologic Scaffold in adult men undergoing robotic assisted radical prostatectomy as compared to control arm.
The study is a multi-center, single blind, randomized, controlled trial. Up to 266 participants will be treated at up to 30 centers in the United States. The study will consist of a Baseline visit, implantation during robotic assisted radical prostatectomy (RARP), catheter removal, 6 weeks, 6 months, 12 months...  Read More             
        
        
    Gender:
                MALE
            Ages:
                45 years and above
            Trial Updated:
                08/22/2025
            
            Locations: Urology of Virginia, PLLC, Virginia Beach, Virginia         
        
        
            Conditions: Radical Prostatectomy, Stress Urinary Incontinence (SUI)
        
            
        
    
                
                                    The AIRTIVITY® Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
                                
            
            
        Recruiting
                            
            
                This study is open to adults with bronchiectasis. People can participate in this study if they produce sputum and have had flare-ups (also called exacerbations).
The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis. Participants are put into 2 groups randomly, which means by chance. One group takes BI 1291583 tablets and the other group takes placebo tablets. A placebo tablet looks like the BI 1291583 tablet but does not contain any medi...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/22/2025
            
            Locations: Inova Fairfax Medical Campus, Falls Church, Virginia         
        
        
            Conditions: Bronchiectasis
        
            
        
    
                
                                    Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
                                
            
            
        Recruiting
                            
            
                Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/22/2025
            
            Locations: Investigative Site US027, Norfolk, Virginia         
        
        
            Conditions: Hidradenitis Suppurativa (HS)
        
            
        
    
                
                                    A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
                                
            
            
        Recruiting
                            
            
                The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/22/2025
            
            Locations: Inova Neurology, Fairfax, Virginia         
        
        
            Conditions: Parkinson Disease
        
            
        
    
                
                                    A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.             
        
        
    Gender:
                MALE
            Ages:
                18 years and above
            Trial Updated:
                08/22/2025
            
            Locations: University of Virginia Cancer Center, Charlottesville, Virginia         
        
        
            Conditions: Metastatic Castration-resistant Prostate Cancer
        
            
        
    
                
                                    A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD
                                
            
            
        Recruiting
                            
            
                PARAMOUNT is a prospective randomized open-label trial testing the hypothesis that a personalized management strategy in symptomatic patients with suspicion of coronary artery disease (CAD), using a CT-based coronary atherosclerotic plaque assessment by AI-enabled quantitative software improves: certainty for diagnosis of CAD, control of CAD risk factors and efficiency of ICA referral with appropriate PCI compared to the usual care strategy based on current AHA/ACC guidelines for care of symptom...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/22/2025
            
            Locations: Chippenham and Johnston Willis Hospitals, Richmond, Virginia         
        
        
            Conditions: Coronary Artery Disease
        
            
        
    
                
                                    A Trial of Felzartamab in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR)
                                
            
            
        Recruiting
                            
            
                The main goal of this trial is to evaluate the efficacy of felzartamab compared to placebo in kidney transplant recipients diagnosed with late active or chronic active AMR.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                08/22/2025
            
            Locations: Virginia Commonwealth University, Richmond, Virginia         
        
        
            Conditions: Antibody-mediated Rejection
        
            
        
    